<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04675541</url>
  </required_header>
  <id_info>
    <org_study_id>OPERA study</org_study_id>
    <secondary_id>2017-A03517-46</secondary_id>
    <nct_id>NCT04675541</nct_id>
  </id_info>
  <brief_title>Register of Patients With haEmophilia A tReated With Afstyla®</brief_title>
  <acronym>OPERA</acronym>
  <official_title>Observational Register of Patients With haEmophilia A tReated With Afstyla®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Record real life data of patients with Hemophilia A and treated with Afstyla® to assess the&#xD;
      effectiveness and the safety of the treatment used as prophylaxis, prevention of bleeding&#xD;
      (e.g. surgery) or on-demand treatment during 3 years after patient inclusion&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Haemophilia A is a congenital coagulation disorder caused by a deficiency or abnormality of&#xD;
      coagulation factor VIII (FVIII).&#xD;
&#xD;
      The severity of the haemophilia depends on the magnitude of the FVIII deficiency and the&#xD;
      clinical features depend on the site of the bleed.&#xD;
&#xD;
      The therapeutic management of this disease involves administering the deficient factor, FVIII&#xD;
      to the patient. Depending on the severity of the disease and patient background, the&#xD;
      management regimens are different (long term prophylactic treatment to prevent non surgical&#xD;
      bleeds, prophylactic short term treatment to prevent surgical bleeds or treatment of acute&#xD;
      bleeds on demand).&#xD;
&#xD;
      Several recombinant or plasma derived treatments are currently available. The CSL Behring&#xD;
      Company has designed a new recombinant single chain B1FVIII, rFVIII (Afstyla®). This has&#xD;
      increased affinity for VWF, resulting in improved stability and an improvement in its&#xD;
      pharmacokinetic indices. OPERA is a non-interventional, prospective and national study which&#xD;
      aim is to record real life data in haemophilia A French patients treated with Afstyla® in&#xD;
      order to confirm the efficacy and safety of this proprietary product established in clinical&#xD;
      development studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2018</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The annualized bleeding rate (spontaneous, traumatic) during long term prophylactic and on demand regimen.</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of spontaneous bleeding episodes per patient</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of infusions of Afstyla® required for the prevention and resolution of non-surgical bleeding episodes</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The total dose of Afstyla® required for the prevention and resolution of non-surgical bleeding episodes</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of infusions of Afstyla® required during the surgical procedures</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total dose of Afstyla® required during the surgical procedures</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse events (AE), severe AE, and AE related to Afstyla®</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Haemophilia A</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Afstyla®</intervention_name>
    <description>Solution for injection</description>
    <other_name>CSL627</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Haemophilia A French patients treated with Afstyla®&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have given their agreement to take part in the observational registry after being&#xD;
             informed in writing of the purposes of the study and after their data have been&#xD;
             recorded (parent's agreement for minor patients);&#xD;
&#xD;
          -  Be suffering from haemophilia A and being treated or having been treated with Afstyla®&#xD;
             long term prophylactically, on demand or preventatively for a surgical procedure;&#xD;
&#xD;
          -  Absence of inhibitor and/or treatment for immune tolerance at the time of inclusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal of the patient or the patient's legal representative to take part in the&#xD;
             study;&#xD;
&#xD;
          -  Existence of a contraindication to the use of Afstyla® treatment (known&#xD;
             hypersensitivity to FVIII or hamster proteins);&#xD;
&#xD;
          -  Simultaneous participation in an interventional clinical study.&#xD;
&#xD;
          -  Presence of an inhibitor and/or ongoing immune tolerance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring SA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Registration Coordinator</last_name>
    <phone>610-878-4000</phone>
    <email>clinicaltrials@cslbehring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Chambéry</name>
      <address>
        <city>Chambéry</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Simone Veil</name>
      <address>
        <city>Eaubonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CRC-MHC Hôpital Kremlin Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FVIII</keyword>
  <keyword>Coagulation FVIII</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

